Replimune is cutting jobs at its Massachusetts sites after the FDA issued a second rejection to its advanced melanoma candidate RP1. The company plans to eliminate 224 positions under WARN notices across its Woburn headquarters and Framingham manufacturing operations, citing the lack of timely accelerated approval pathway.